Opko Health, INC. (OPK) — SEC Filings

Q: What are the key financial highlights for Opko Health, INC.?

Key financial highlights for Opko Health, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Opko Health, INC.?

Key executives at Opko Health, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Opko Health, INC. stock?

Risk factors for Opko Health, INC. (OPK) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Opko Health, INC.?

Forward-looking statements and predictions from Opko Health, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Opko Health, INC.. Recent 8-K filing on Oct 29, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Opko Health, INC. on SEC EDGAR

Overview

Opko Health, INC. (OPK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Oct 29, 2025: On October 29, 2025, OPKO Health, Inc. filed an 8-K report. The filing indicates a change in the company's financial condition and results of operations. It also includes financial statements and exhibits related to these changes.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Opko Health, INC. is neutral.

Filing Type Overview

Opko Health, INC. (OPK) has filed 19 8-K, 5 10-Q, 1 10-K/A, 2 DEF 14A, 2 10-K, 11 SC 13D/A, 1 SC 13G, 3 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Oct 2025.

Filings by Year

2025 · 2024

Recent Filings (45)

OPKO Health Files 8-K on Financials — 8-K · Oct 29, 2025 Risk: medium
On October 29, 2025, OPKO Health, Inc. filed an 8-K report. The filing indicates a change in the company's financial condition and results of operations. It als
OPKO Health Files 8-K Report — 8-K · Sep 15, 2025 Risk: low
On September 15, 2025, OPKO Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Reg
OPKO Health Q2 Revenue Drops 13%, Net Loss Widens to $50.3M — 10-Q · Jul 31, 2025 Risk: high
OPKO Health, Inc. reported a significant decrease in revenue for the three months ended June 30, 2025, falling to $178.5 million from $205.1 million in the prio
OPKO Health Announces Executive and Director Changes — 8-K · May 29, 2025 Risk: medium
On May 27, 2025, OPKO Health, Inc. filed an 8-K report detailing changes in its executive and director roles. The filing includes information on the departure o
OPKO Health Q1 2025: Assets Top $1.25B — 10-Q · May 1, 2025 Risk: medium
OPKO Health, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $1.25 billion and total liabilities of $701.4 millio
OPKO Health Files 8-K with Financial Updates — 8-K · Apr 30, 2025 Risk: medium
On April 30, 2025, OPKO Health, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits,
OPKO Health Files 8-K on Security Holder Vote — 8-K · Apr 23, 2025 Risk: low
On April 23, 2025, OPKO Health, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not provide det
OPKO Health Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 1, 2025 Risk: medium
On March 28, 2025, OPKO Health, Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The company, incorporate
OPKO Health Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 28, 2025 Risk: medium
On March 27, 2025, OPKO Health, Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The company, incorporate
OPKO Health Files 2024 Annual Report Amendment — 10-K/A · Mar 21, 2025 Risk: low
OPKO Health, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated March 21, 2025, is an amendmen
OPKO Health DEF 14A: Executive Comp & Equity Awards — DEF 14A · Mar 14, 2025 Risk: medium
OPKO Health, Inc. filed its DEF 14A on March 14, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31,
OPKO Health Enters Material Definitive Agreement — 8-K · Mar 11, 2025 Risk: medium
On March 10, 2025, OPKO Health, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements a
OPKO Health Files 2024 Annual Report — 10-K · Mar 3, 2025 Risk: medium
OPKO Health, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $781,936,885 and total liabilities of $29,79
OPKO Health Files 8-K on Financials — 8-K · Feb 27, 2025 Risk: low
On February 27, 2025, OPKO Health, Inc. filed an 8-K report detailing its financial results and operations. The filing includes information on the company's fin
OPKO Health Files 8-K Report — 8-K · Jan 15, 2025 Risk: low
On January 15, 2025, OPKO Health, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spe
OPKO HEALTH amends GeneDx Holdings stake filing — SC 13D/A · Nov 20, 2024 Risk: medium
OPKO HEALTH, INC. filed an amendment to its Schedule 13D on November 20, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates
Frost Trusts Amend OPKO Health Stake — SC 13D/A · Nov 15, 2024 Risk: medium
Frost Gamma Investments Trust and Frost Nevada Investments Trust, managed by Phillip Frost, MD, have filed an amendment (No. 25) to their Schedule 13D for OPKO
SC 13G Filing — SC 13G · Nov 13, 2024
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
OPKO Health Files 13D/A Amendment for GeneDx Holdings — SC 13D/A · Nov 8, 2024 Risk: medium
OPKO Health, Inc. filed an amendment to its Schedule 13D on November 8, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a
OPKO Health Q3 Revenue Surges to $29.8M — 10-Q · Nov 7, 2024 Risk: medium
OPKO Health, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1.25 billion and total liabilities of $781.9 mi
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
OPKO Health Files 13D/A Amendment on GeneDx Holdings — SC 13D/A · Sep 18, 2024 Risk: medium
OPKO Health, Inc. filed an amendment to its Schedule 13D on September 18, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates
OPKO Health Files 8-K on Agreement Termination & Asset Deal — 8-K · Sep 16, 2024 Risk: medium
On September 16, 2024, OPKO Health, Inc. filed an 8-K to report the termination of a material definitive agreement and the completion of an acquisition or dispo
Frost MD Amends OPKO Health Stake Filing — SC 13D/A · Aug 29, 2024 Risk: low
Phillip Frost MD and others filed an amendment (No. 24) to their Schedule 13D on August 29, 2024, regarding their holdings in OPKO Health, Inc. The filing indic
OPKO Health Files 13D/A Amendment on GeneDx Holdings Corp. — SC 13D/A · Aug 23, 2024 Risk: medium
OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. as of August 23, 2024. Th
OPKO HEALTH, INC. Amends Filing for GeneDx Holdings Corp. — SC 13D/A · Aug 12, 2024 Risk: medium
On August 12, 2024, OPKO HEALTH, INC. filed an SC 13D/A amendment regarding GeneDx Holdings Corp. The filing indicates a change in beneficial ownership, with OP
OPKO Health Q2 2024: Assets $1.25B, Liabilities $727M — 10-Q · Aug 7, 2024 Risk: medium
OPKO Health, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $1.25 billion and total liabilities of $727.18 millio
OPKO Health Appoints New CMO, Elects Director — 8-K · Jul 29, 2024 Risk: medium
OPKO Health, Inc. announced on July 24, 2024, the appointment of Dr. Adam M. Pezeshki as Chief Medical Officer and the election of Dr. Phillip P. Lopez to its B
OPKO Health Files 13D/A Amendment for GeneDx Holdings Corp. — SC 13D/A · Jul 26, 2024 Risk: medium
OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. The filing, dated July 26
OPKO Health Files 8-K on Material Agreement & Financial Obligation — 8-K · Jul 17, 2024 Risk: medium
On July 17, 2024, OPKO Health, Inc. filed an 8-K report detailing a material definitive agreement and a direct financial obligation. The filing indicates the co
OPKO Health Files 13D/A Amendment on GeneDx Holdings — SC 13D/A · Jul 5, 2024 Risk: medium
OPKO Health, Inc. filed an amendment to its Schedule 13D on July 5, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a cha
OPKO Health Q1 2024: Revenue Dip, Asset/Liability Shift — 10-Q · May 7, 2024 Risk: high
OPKO Health, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported total assets of $726,791,854 and total liabilities of $781,936,885.
OPKO Health Files 8-K on Security Holder Vote — 8-K · Mar 29, 2024 Risk: low
On March 28, 2024, OPKO Health, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not disclose sp
OPKO Health Files 8-K/A Amendment — 8-K/A · Mar 28, 2024 Risk: low
OPKO Health, Inc. filed an 8-K/A on March 28, 2024, to amend a previous filing. The amendment pertains to Regulation FD Disclosure and Financial Statements and
OPKO HEALTH, INC. Files 2023 Annual Report on Form 10-K — 10-K · Mar 1, 2024 Risk: medium
OPKO HEALTH, INC. (OPK) filed a Annual Report (10-K) with the SEC on March 1, 2024. OPKO HEALTH, INC. filed its annual report for the fiscal year ended December
OPKO Health Announces 2024 Annual Meeting of Stockholders on March 28 — DEF 14A · Feb 29, 2024 Risk: low
OPKO HEALTH, INC. (OPK) filed a Proxy Statement (DEF 14A) with the SEC on February 29, 2024. Annual Meeting scheduled for March 28, 2024, held virtually. Propos
OPKO Health Files 8-K for Financial Results — 8-K · Feb 27, 2024 Risk: medium
OPKO Health, Inc. filed an 8-K on February 27, 2024, to report its "Results of Operations and Financial Condition" and include "Financial Statements and Exhibit
Vanguard Trims OPKO Health Stake to 8.04% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on February 13, 2024, indicating a change in its ownership of OPKO Health Inc. comm
OPKO Health Reports Officer Changes & Compensation Arrangements — 8-K · Feb 9, 2024 Risk: medium
OPKO Health, Inc. filed an 8-K on February 9, 2024, reporting a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic
Dr. Phillip Frost Amends OPKO Health Stake, Signals Ownership Change — SC 13D/A · Jan 24, 2024
Dr. Phillip Frost, a significant insider, filed an Amendment No. 23 to his Schedule 13D on January 22, 2024, indicating a change in his beneficial ownership of
Dr. Phillip Frost Trims OPKO Health Stake to 30.6% — SC 13D/A · Jan 22, 2024
Dr. Phillip Frost, through Frost Gamma Investments Trust and Frost Nevada Investments Trust, has updated his beneficial ownership in OPKO Health, Inc. (OPK) as
OPKO Health: New Material Agreement, Termination, & Financial Obligation — 8-K · Jan 9, 2024
OPKO Health, Inc. filed an 8-K on January 9, 2024, reporting events from January 4, 2024, including the entry into and termination of a material definitive agre
OPKO Health Files 8-K for 'Other Events' and Exhibits — 8-K · Jan 5, 2024
OPKO Health, Inc. filed an 8-K on January 4, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing, under the ticker OPK on the NA
OPKO Health Updates Business Address, Phone, Confirms NASDAQ Listing — 8-K · Jan 4, 2024
OPKO Health, Inc. filed an 8-K on January 3, 2024, to update its corporate information, specifically its business address to 4400 Biscayne Blvd., Miami, Florida

Risk Profile

Risk Assessment: Of OPK's 37 recent filings, 2 were flagged as high-risk, 25 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Opko Health, INC.'s most recent 10-Q filing (Jul 31, 2025):

Revenue: $178.5M
Net Income: -$50.3M
EPS: -$0.06

Key Executives

Phillip Frost, MD
Camielle Green
Phillip Frost MD
Dr. Adam M. Pezeshki
Dr. Phillip P. Lopez

Industry Context

The pharmaceutical and diagnostics industries are characterized by intense competition, significant R&D investment, and evolving regulatory landscapes. Companies are focused on developing innovative therapies and diagnostic tools to address unmet medical needs. The market for treatments like GLP-1 agonists is growing rapidly, driven by increasing rates of obesity and type 2 diabetes.

Top Tags

amendment (13) · sec-filing (11) · ownership-change (8) · corporate-governance (6) · financials (5) · material-agreement (4) · 10-Q (3) · disclosure (3) · filing (2) · 8-K (2)

Key Numbers

Total Revenue: $178.5M — Decreased from $205.1 million in Q2 2024, a 13% decline.
Net Loss: $50.3M — Widened from $38.7 million in Q2 2024.
Loss Per Share: $0.06 — Increased from $0.05 per share in Q2 2024.
Pharmaceutical Segment Revenue: $35.2M — Decreased from $42.8 million in Q2 2024.
Diagnostic Segment Revenue: $143.3M — Decreased from $162.3 million in Q2 2024.
Revenue Decline: 13% — Percentage decrease in total revenue year-over-year for Q2.
Total Assets: $1.25B — As of March 31, 2025, indicating the company's total resources.
Total Liabilities: $701.4M — As of March 31, 2025, representing the company's total obligations.
Current Liabilities: 29,799,907 — As of March 31, 2025, showing short-term financial obligations.
SEC File Number: 001-33528 — Identifies the company's filing history with the SEC.
IRS Employer Identification No.: 75-2402409 — Company's tax identification number.
IRS Number: 75-2402409 — Company's Employer Identification Number.
Fiscal Year End: 2024 — The period covered by the compensation and equity award data in the filing.
Filing Date: 20250314 — The date OPKO Health submitted this DEF 14A to the SEC.
Authorized Shares: 1,250,000,000 — Common stock authorized

Forward-Looking Statements

{"claim":"The slight reduction in Vanguard's stake will have a minimal impact on OPKO Health's stock price in the short term.","entity":"OPKO Health Inc.","targetDate":"2024-03-13","confidence":"medium"}
{"claim":"Vanguard will continue to hold a significant, but potentially fluctuating, passive stake in OPKO Health.","entity":"The Vanguard Group","targetDate":"2025-02-13","confidence":"high"}

Related Companies

LH · DGX · GHDX

Frequently Asked Questions

What are the latest SEC filings for Opko Health, INC. (OPK)?

Opko Health, INC. has 45 recent SEC filings from Jan 2024 to Oct 2025, including 19 8-K, 11 SC 13D/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of OPK filings?

Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Opko Health, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Opko Health, INC. (OPK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Opko Health, INC.?

Key financial highlights from Opko Health, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for OPK?

The investment thesis for OPK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Opko Health, INC.?

Key executives identified across Opko Health, INC.'s filings include Phillip Frost, MD, Camielle Green, Phillip Frost MD, Dr. Adam M. Pezeshki, Dr. Phillip P. Lopez.

What are the main risk factors for Opko Health, INC. stock?

Of OPK's 37 assessed filings, 2 were flagged high-risk, 25 medium-risk, and 10 low-risk.

What are recent predictions and forward guidance from Opko Health, INC.?

Recent forward-looking statements from Opko Health, INC. include guidance on {"claim":"The slight reduction in Vanguard's stake will have a minimal impact on OPKO Health's stock price in the short and 1 other predictions.